Navigation Links
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
Date:8/11/2009

dicine and the director of Genitourinary Medical Oncology at Massachusetts General Hospital Cancer Center. "In this large international study, denosumab markedly increased bone mineral density and decreased the risk of fractures in many men receiving androgen deprivation therapy for prostate cancer. The efficacy of denosumab was apparent as early as one month and was sustained for three years."

In the HALT trial, the overall incidence and type of side effects with denosumab were similar to placebo. Rates of AEs were similar in both groups (87 percent). Rates of serious AEs were 35 percent for denosumab and 31 percent for placebo. The most common AEs across both treatment arms were arthralgia, back pain, constipation, pain in extremity, and hypertension. There were no reported cases of osteonecrosis of the jaw among patients treated with denosumab. More patients receiving denosumab developed cataracts, though none were considered treatment-related. One patient in the denosumab arm developed hypocalcemia, versus none in the placebo arm. New primary malignancies were reported in 5 percent of patients in each group. Serious AEs of infections were reported in 6 percent of denosumab-treated patients and in 5 percent of placebo-treated patients.(2)

"Amgen scientists in the 1990s were the first to identify the RANK Ligand pathway, a pivotal physiologic mechanism that controls bone remodeling," said Roger Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "Today's publications in the New England Journal of Medicine underscore the significance of this finding, and highlight Amgen's focus on using innovative research to address grievous illness."

About Denosumab

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break do
'/>"/>

SOURCE Amgen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014 MC Medical, a subsidiary of ... Columbus, OH medical device company, have ... laparoscopic and robotic visualization system in Japan ... sale in Japan in the latter ... and an extensive product portfolio in endoscopic surgery market in ...
(Date:8/22/2014)... , Aug. 22, 2014   Zacks Equity Research highlights ... of the Day and Panera (Nasdaq: PNRA - Free Report ... Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free ... Shire (Nasdaq: SHPG - Free Report ). Here ... Bull of the Day : The biotech bull ...
(Date:8/22/2014)... LA JOLLA , Cali ., Aug. ... Annual International Papillomavirus Conference shows that a therapy being developed ... including the two that cause 70 percent of all cervical ... models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker , Ph.D., who presented the findings at ...
Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... Frankfurt am Main Emergency Medical Services (EMS) ... MASI ), the inventor of rainbow® Pulse CO-Oximetry™, rainbow ... Perfusion pulse oximetry, today jointly announced that every EMS ... equipped with a Masimo Rad-57® Pulse CO-Oximeter—making carbon monoxide ...
... Aug. 26 Cardioxyl Pharmaceuticals, Inc. , a ... of cardiovascular disease, today announced that it has initiated ... candidate, CXL-1020, for the treatment of patients with acute ... for patients at the time of discharge from U.S. ...
Cached Medicine Technology:Frankfurt am Main Emergency Medical Services Makes Masimo Rad-57 Pulse CO-Oximeters Mandatory for All Vehicles 2Frankfurt am Main Emergency Medical Services Makes Masimo Rad-57 Pulse CO-Oximeters Mandatory for All Vehicles 3Frankfurt am Main Emergency Medical Services Makes Masimo Rad-57 Pulse CO-Oximeters Mandatory for All Vehicles 4Frankfurt am Main Emergency Medical Services Makes Masimo Rad-57 Pulse CO-Oximeters Mandatory for All Vehicles 5Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients 2Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients 3Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients 4
(Date:8/23/2014)... Cardiomyopathy (heart muscle disease) is ... myocardium (the heart muscle) for any reason, usually ... (breathlessness) and peripheral edema (swelling of the legs). ... dangerous forms of irregular heart beat and sudden ... is dilated cardiomyopathy. , Clinical trial report, “Cardiomyopathy ...
(Date:8/23/2014)... New York (PRWEB) August 23, 2014 ... from the 2012 GranuFlo and NaturaLyte dialysis concentrate ... litigation underway in U.S. District Court, District of ... updated docket report issued by the U.S. Judicial ... at least 2,028 claims are pending in the ...
(Date:8/23/2014)... "When men sit down to use the toilet, ... water inside the bowl, the interior rim of the ... inventors from Naugatuck, and Bridgeport, Conn. "In order to ... , They developed the IPSAFE to prevent the penis ... and seat. This minimizes exposure to germs, which helps ...
(Date:8/23/2014)... New York, NY (PRWEB) August 23, 2014 ... Times (NYT) reported on a data breach suffered ... nationwide, that saw the compromise of 4.5 million records ... and social security numbers. According to Mandiant, who was ... attack emanated from an advanced group of cyber ...
(Date:8/23/2014)... 2014 Pixel Film Studios, a leader of ... release of ProIntro Vol.3, a customizable title tool for ... tile just by dragging ProIntro Vol.3 in their timeline" says ... a definite time saver and i think our users will ... beautifully designed titles made with Final Cut Pro X users ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 4Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2
... New advisory puts worries about possible link to heart disease ... that discussion about the omega-6 fatty acids found in vegetable ... is unfounded, a new science advisory from the American Heart ... in the nutrition world that omega-6 fatty acids might be ...
... Jan. 26 Cooperative of American Physicians, Inc. Chief ... 2009 recipient of the Spirit of Life(R) ... gala black tie dinner celebrating Mr. Weidner and his ... in Pasadena, California on Saturday, November 14. Spirit of ...
... Exclusive Retail Partner WARREN, N.J., Jan. 26 ... announced today that it is joining the fight ... LG Pink Flare limited edition handset, available exclusively ... http://www.newscom.com/cgi-bin/prnh/20090126/NY62794 ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20070613/VIRGINMOBILE ...
... EDGE, N.J., Jan. 26 Nephros, Inc. (Pink Sheets: ... products for therapeutic applications, infection control, and water purification, ... in the Pink Sheets under the symbol "NEPH." ... been suspended from trading on the NYSE Alternext US ...
... overestimate the dangers, study finds, , , MONDAY, Jan. 26 ... U.S. minorities and the disabled more so than on ... as well as the disabled and mentally ill, are ... terrorism fears, such as avoiding certain activities. These ...
... Airlines to Fly 14 Teenage Amputees for a Week-Long ... Airlines and Texas Scottish Rite Hospital for Children have ... on an all-expense-paid ski trip to Winter Park, Colo., ... departs from Dallas/Fort Worth International Airport (DFW) today and ...
Cached Medicine News:Health News:Omega-6 Fatty Acids Can Be Good for You 2Health News:Omega-6 Fatty Acids Can Be Good for You 3Health News:James L. Weidner Named 2009 Spirit of Life(R) Award Recipient by City of Hope 2Health News:Virgin Mobile USA Launches Limited Edition Pink Flare Handset to Benefit Susan G. Komen for the Cure(R) 2Health News:Virgin Mobile USA Launches Limited Edition Pink Flare Handset to Benefit Susan G. Komen for the Cure(R) 3Health News:Nephros Common Stock Now Quoted in Pink Sheets 2Health News:Nephros Common Stock Now Quoted in Pink Sheets 3Health News:Terror Fears Tougher on Minorities, Disabled 2Health News:Terror Fears Tougher on Minorities, Disabled 3Health News:American Airlines and Texas Scottish Rite Hospital for Children Host Annual Amputee Ski Trip 2Health News:American Airlines and Texas Scottish Rite Hospital for Children Host Annual Amputee Ski Trip 3
Katena ophthalmic burr for polishing pterygiums, includes one round diamond burr and has an storage case....
Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Trial Lens Sets....
... is the first ... to offer two kinds ... and taurine. Cleans, rinses, ... and conditions any soft ...
Medicine Products: